Eli Lilly shares advance with price holding over all major moving averages: weekly forecast

Traders Union
All News
Financial News
Eli Lilly rises 2.12% this week

Highlights

Eli Lilly continues to show robust bullish momentum, consistently trading above major moving averages and hitting new highs.
Technical indicators signal an overbought condition with elevated volatility, suggesting potential for near-term consolidation or a brief pullback.
The projected trading range for the week is $1,218 to $1,273, with a prevailing 75% probability of further upside unless profit-taking triggers a retreat toward support.

Expansion initiatives and drug launches lift sentiment during the week

Eli Lilly recently initiated a $3.5 billion expansion in Pennsylvania's Lehigh Valley, a move expected to create 2,850 jobs and representing the state's largest life sciences investment. The company launched its oral obesity drug Foundayo and reported positive late-stage clinical trial results for retatrutide targeting adults with obesity and obstructive sleep apnea. LLY also entered a strategic partnership with DKSH for pharmaceutical distribution in Hong Kong SAR and Macau SAR.

Overbought signals emerge amid persistent bullish momentum this week

Weekly technical analysis confirms ongoing bullish momentum, with LLY trading well above all key weekly moving averages and the nearest dynamic support now at MA-50 ($957.52). The price remains more than 30% above the Ichimoku Kijun ($1,044.26), while weekly indicators such as MACD and ADX show robust upward strength. However, RSI is overbought, Stochastic RSI and CCI register overbought as well, and Bull/Bear Power reflects strong buying — all suggesting that while momentum is positive, near-term cooling or consolidation is possible. The Awesome Oscillator further reinforces the bullish environment, and LLY is currently at the top of its weekly range with volatility at 4.87%.

Breakout risk and consolidation eyed for LLY in the coming week

Looking ahead to the next five trading days, LLY is expected to consolidate within a range of $1,218 to $1,273. There is about a 75% probability of further upside continuation, supported by three out of four key weekly indicators signaling Buy or Strong Buy. Should momentum persist, a breakout above $1,273 may prompt additional gains, whereas a bearish scenario could see the price retreat toward $1,218 as the market addresses overbought conditions and tests dynamic support.

Anton Kharitonov, analyst at Traders Union, notes that Eli Lilly (LLY) continued its uptrend this week, closing 2.12% higher and sustaining strong bullish momentum above all key weekly moving averages. He observes that the $3.5 billion Pennsylvania expansion and new product launches are supporting positive sentiment, but technical signals now show clear signs of overbought conditions. Kharitonov cautions that the combination of robust upward indicators and overstretched oscillators means the rally could pause or consolidate in the coming week. The expected range is $1,218 to $1,273, with dynamic support at the MA-50 and 75% odds favoring further upside as long as buyers remain in control. However, risk of a pullback is elevated due to the persistent overbought readings. "Despite strong fundamental news and technical momentum, I remain cautious this week — unless LLY can firmly break above $1,273, I expect potential for near-term consolidation or a test of lower support."

Previously it was reported that regulators have opened new reimbursement pathways for Eli Lilly’s obesity treatments under a Medicare pilot, potentially expanding market access and supporting long-term growth. The latest technical and corporate developments reinforce the company’s bullish outlook, with LLY’s prevailing uptrend and sector momentum positioning $1,273 as a key breakout level for further gains in the upcoming week.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.